孕婴血清病毒状态与hbv宫内传播的关系探讨

《孕婴血清病毒状态与hbv宫内传播的关系探讨》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码,10089学号或申请号13631HebeiMedicalUniversity硕士学位论文在职科学学位孕婴血清病毒状态与HBV宫内传播的关系探讨学位申请人：陈志英导师：单保恩教授专业：免疫学二级学院：第四医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师(或指导小组)的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用-凡发表与学位论文主耍内容相关的论文，第一署名为单位河北医科大学，

2、试验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则,承担相应法律责任。研究生签名:辦4导师签章系通,二级学院领导盖章:年月河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果,除了文中特别加以标注和致谢等内容外,文中不包含其他人已经发表或撰写的研究成果,指导教师对此进行了审定a论文由本人独立撰写，文责自负•研究生签名：拥•对、导师签章：幻过、>月，日目录中文摘要·················································

3、·················································1英文摘要··································································································4英文缩写··························································································7研究论文孕婴血清

4、病毒状态与HBV宫内传播的关系探讨前言·····························································································8材料与方法·························································································8结果··············································

5、···············································11附表·······························································································15讨论·································································································18结论·····

6、····················································································22参考文献··················································································22综述乙型肝炎的母婴传播机制及阻断研究进展·····································25致谢·····················

7、··················································································31个人简历··················································································32中文摘要孕婴血清病毒状态与HBV宫内传播的关系探讨摘要目的：检测HBV感染孕妇及新生儿血清乙肝病毒标志物和HBV-DNA水平变化，分析HBV宫内感染机制及宫内传播的影响

8、因素，完善乙型肝炎母婴阻断策略，更大限度的降低HBV感染率。方法：1收集2013年1月—2013年6月在石家庄市妇幼保健院生产的HBsAg阳性孕妇318例，采集孕妇静脉血及新生儿脐带血。记录孕妇基本信息、孕晚期抗病毒治疗情况、分娩方式及新生儿出生时基本情况。2按照我国《慢性乙肝防治指南》，新生儿在出生即刻注射高效价乙肝免疫球蛋白200IU，并在出生时和出生后1月龄、6月龄注射重组乙肝疫苗（CHO）20微克，完成全